Vertex PharmaceuticalsActive
An oral, once-daily somatostatin receptor agonist for acromegaly, acquired through the Crinetics Pharmaceuticals deal - Vertex's first marketed product outside CF, pain, and gene therapy, and the anchor of its new endocrine-disease business.
Latest update Sep 8, 2026
01
Approved in the US in September 2025 and by the European Commission on April 27, 2026 - the first once-daily oral acromegaly therapy in both markets. Joined Vertex's portfolio when the Crinetics acquisition closed on September 1, 2026. Also in Phase 3 for carcinoid syndrome associated with neuroendocrine tumors.
02
03
Announced next steps from Vertex Pharmaceuticals that mention Palsonify (paltusotine).
Late 2026
Having closed the ~$10B Crinetics acquisition on September 1, 2026, Vertex must integrate the Palsonify commercial business (US-launched, EU-approved April 27, 2026) and the atumelnant pipeline (Phase 3 CAH, Phase 2 Cushing's). Charles Wagner expanded his COO remit to include the integration; Jonathan Poole becomes EVP and CFO on January 1, 2027. Jasper van Grunsven started September 8, 2026 as EVP and Chief Pain and New Product Planning Officer. Updated 2026 financial guidance that includes Crinetics is due with Q3 results on November 2, 2026.
04
Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals on September 1, 2026, a deal worth about $10.0 billion in total equity value (roughly $8.8 billion net of acquired cash), after clearing shareholder and antitrust approvals. The deal adds the marketed acromegaly drug Palsonify (paltusotine) and pipeline candidate atumelnant, and Vertex announced an expanded executive leadership team, naming Jonathan Poole EVP and Chief Financial Officer and adding Jasper van Grunsven as EVP, Chief Pain and New Product Planning Officer, to support the new endocrine-disease business.
Crinetics Pharmaceuticals shareholders voted on August 28, 2026 to approve Vertex Pharmaceuticals' $85-per-share, roughly $10 billion cash acquisition, clearing the final outstanding condition after antitrust clearances were received in the US, Austria, Germany, and Australia. The deal, Vertex's largest ever, brings it the marketed acromegaly drug Palsonify and an endocrinology pipeline including atumelnant, with the companies now expecting the transaction to close around September 1, 2026.
Vertex Pharmaceuticals agreed on July 6 to acquire endocrine-disease specialist Crinetics Pharmaceuticals for $85 per share in cash, valuing the San Diego company at roughly $10 billion - Vertex's largest acquisition to date and about a 102% premium to Crinetics' prior close. The deal hands Vertex Palsonify (paltusotine), an oral once-daily drug approved in September 2025 for acromegaly, plus an endocrinology pipeline the companies say could deliver more than $5 billion in combined peak annual revenue. Approved by both boards, the transaction is expected to close in the third quarter of 2026 and become accretive to non-GAAP operating income in 2029.
05
Vertex's flagship cystic fibrosis triple-combination CFTR modulator (elexacaftor/tezacaftor/ivacaftor), effective for roughly 90% of CF patients and the company's dominant revenue engine - now complemented by the once-daily next-generation Alyftrek.
A first-in-class oral, non-opioid pain medicine (VX-548) that selectively inhibits the NaV1.8 sodium channel to block pain signals in the peripheral nervous system before they reach the brain - the first new class of pain drug in over 20 years.
The first approved CRISPR/Cas9 gene-editing medicine (exagamglogene autotemcel), a one-time therapy for sickle cell disease and transfusion-dependent beta thalassemia, developed and commercialized with CRISPR Therapeutics.
An allogeneic, stem-cell-derived, fully differentiated islet cell therapy for type 1 diabetes designed to restore the body's own insulin production - a potential functional cure delivered as a one-time infusion.
06
Oklo
Oklo's fast-fission powerhouse product line is designed for build-own-operate deployment, targeting customers that want firm clean power in a smaller footprint than traditional large reactors.
Oklo
Oklo is developing an advanced fuel center to recycle used nuclear fuel and fabricate metal fuel for Aurora and other fast-reactor applications.
TerraPower
Sodium-cooled fast reactor with integrated molten salt energy storage, enabling flexible output from 345 MWe to 500 MWe peak.
TerraPower
Integrated thermal energy storage system using molten salt to decouple reactor output from grid delivery, enabling peak power output.